Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Genentech has shared positive data from the Phase III REGENCY trial with regulators in the US and EU. Roche’s subsidiary ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Roche has reported positive results from its Phase III REGENCY trial of Gazyva (obinutuzumab) for the treatment of lupus ...

Atherosclerosis cardiovascular disease (ASCVD)-related mortality is higher in patients with lupus nephritis (LN) compared ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a detailed analysis of its phase III REGENCY trial of Gazyva®/Gazyvaro® (obinutuzumab) in people with active lupus nephritis (LN) was published ...

Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

The FDA has granted Fast Track Designation to Adicet Bio’s ADI-001, an allogeneic gamma delta CAR T-cell therapy, for ...

Genentech, a member of Roche (RHHBY), announced that a detailed analysis of its Phase III REGENCY trial of Gazyva in people with active lupus ...

Buying Alexion remains a “fantastic acquisition” for AstraZeneca, the Big Pharma’s CEO has said, even as the company takes a ...

Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids earlier, than those using standard immunotherapy, according to data published in ...

The chronic kidney disease drug development landscape is evolving at an unprecedented pace, driven by breakthrough approvals, billion-dollar mergers and acquisitions, and increasing regulatory support ...